Hemostemix, a clinical-stage Canadian-Israeli company, is the newest member of the Centre for Commercialization of Regenerative Medicine’s (CCRM) industry consortium.
Hemostemix develops and commercializes blood-derived therapies for severe medical conditions such as Critical limb ischemia (CLI). CLI is a chronic condition resulting from severe blockage in the arteries of the lower extremities and reducing blood-flow. Complications of poor circulation can include sores and wounds that won’t heal in the legs and feet.
Left untreated, the complications of CLI may result in amputation of the affected limb and death. The incidence of CLI increases with age, smoking, and co-morbidities such as diabetes or cardiac disease. It is estimated to currently afflict approximately three million people in the United States alone.
Through the partnership, CCRM will provide support to Hemostemix through a Phase 2 clinical trial in Canada, and potentially internationally, for patients with CLI.
“CCRM can open doors for Hemostemix that will enable their current and future efforts, and we are pleased to welcome them into the industry consortium,” said Michael May, CEO of the CCRM. He adds that Hemostemix’s expertise with blood-derived therapies and manufacturing cells for patients will also complement the development work taking place at CCRM.
CCRM’s industry consortium currently numbers 35 companies representing the key sectors of the industry: devices, therapeutics, reagents and cells as tools.
To see a complete list of CCRM’s members, click here.